ZBH — Zimmer Biomet Holdings, Inc.

Summary of Zimmer Biomet (ZBH) Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Net Sales: $2.087 billion, up 9.3% reported; 2.9% organic constant currency growth.
• Adjusted EPS: $2.09, a 15% increase year-over-year.
• Gross Margin: 73%, benefiting from tariff-related items and favorable product mix.
• Operating Cash Flow: $359 million; Free Cash Flow: $246 million.
• Share Repurchases: $250 million in Q1, reducing shares outstanding to 195.8 million.

2. Strategic Updates and Business Highlights

• U.S. Sales Growth: Increased 3.2%, driven by strong technology sales and new product launches, particularly in knee and hip segments.
• Go-to-Market Changes: Transition to a specialized sales force is on track, with productivity improvements noted in transitioned territories.
• Innovation and Diversification: Continued focus on technology solutions, including the upcoming Monogram robotic system and strong sales of OrthoGrid and Paragon 28, which is trending back toward double-digit growth.
• Leadership Changes: Dr. Jonathan [indiscernible] appointed as Chief Science Technology and Medical Affairs Officer.

3. Forward Guidance and Outlook

• Revenue Growth Guidance: Maintained at 1% to 3% organic constant currency growth for 2026; reported sales growth guidance remains 2.5% to 4.5%.
• Adjusted EPS Guidance: Raised to $8.40 - $8.55 from $8.30 - $8.45.
• Free Cash Flow Growth: Expected to be in the range of 9% to 11%, up from previous guidance of 8% to 10%.
• Operating Margins: Anticipated to decline slightly, with expectations of approximately 50 basis points decrease from 2025.

4. Bad News, Challenges, or Points of Concern

• Sales Transition Disruptions: Some modest disruptions noted during the transition to a dedicated sales force, with the loss of two significant accounts.
• Market Pressures: Continued pricing erosion expected, with guidance of up to 100 basis points for the year. There are concerns about competitive pressures and macroeconomic factors affecting growth.
• International Growth: International sales growth lagged behind U.S. growth, attributed to distributor changes and difficult comparisons in the first half of the year.

5. Notable Q&A Insights

• Confidence in Growth: CEO Ivan Tornos expressed confidence in the company's direction despite maintaining cautious guidance, citing strong product pipelines and sales force productivity improvements.
• Impact of Competitors: No significant benefit from competitors' operational issues was observed in Q1.
• Market Dynamics: The company is closely monitoring macroeconomic conditions, particularly in the Middle East, but reported no material disruptions.
• Future of Pricing: Tornos indicated that pricing dynamics would be reassessed in the August call, reflecting ongoing market conditions.

Overall, Zimmer Biomet reported a strong start to 2026, with solid financial performance and strategic initiatives underway, though challenges remain in sales transitions and market pressures.